Skip to main content
SpringerLink
Log in

Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma

  • Chapter
  • First Online:
Robotic Surgery for Renal Cancer

Part of the book series: Management of Urology ((MU))

  • 210 Accesses

Abstract

 Since the advent of systemic targeted therapies for metastatic renal cell carcinoma (mRCC) treatment, the role of cytoreductive nephrectomy (CN) has been questioned. Several retrospective observational studies demonstrated a therapeutic benefit for CN, while recent prospective randomized trials have challenged this evidence. In this setting, patient selection, surgical approach and treatment sequence are some of the aspects currently under evaluation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Abel EJ, Spiess PE, Margulis V, et al. Cytoreductive nephrectomy renal cell carcinoma patients with venous tumor thrombus. J Urol. 2017;198:281–8.

    Article  Google Scholar 

  2. Anele UA, Marchioni M, Yang B, et al. Robotic versus laparoscopic radical nephrectomy: a large multi-institutional analysis (ROSULA Collaborative Group). World J Urol. 2019;37(11):2439–50.

    Article  Google Scholar 

  3. Becher E, Jericevic D, Huang WC. Minimally invasive surgery for patients with locally advanced and/or metastatic renal cell carcinoma. Urol Clin N Am. 2020;47:389–97.

    Article  Google Scholar 

  4. Bex A, Mulders P, Jewett M, et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib. The SURTIME Randomized Clinical Trial. JAMA Oncol. 2019;5(2):164–70.

    Google Scholar 

  5. Bhindi B, Abel EJ, Albiges L, et al. Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond: an individualized approach to metastatic renal cell carcinoma. Eur Urol. 2019;75(1):111–28.

    Article  Google Scholar 

  6. Bhindi B, Graham J, Wells C, et al. Deferred cytoreductive nephrectomy in patients with newly diagnosed metastatic renal cell carcinoma. Eur Urol. 2020;78:615–23.

    Article  CAS  Google Scholar 

  7. Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A, et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol. 2012;23:973–80.

    Article  CAS  Google Scholar 

  8. Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017;376:354–66.

    Article  CAS  Google Scholar 

  9. Culp SH, Tannir NM, Abel EJ, et al. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer. 2010;116:3378–88.

    Article  Google Scholar 

  10. Dabestani S, Marconi L, Hofmann F, Stewart F, Lam TBL, Canfield SE, et al. Local treatment for metastases of renal cell carcinoma: a systematic review. Lancet Oncol. 2014;15:549–61.

    Article  Google Scholar 

  11. De Bruijn RE, Mulders P, Jewett MA, et al. Surgical safety of cytoreductive nephrectomy following sunitinib: results from multicentre, randomised controlled trial of immediate versus deferred nephrectomy (SURTIME). Eur Urol. 2019;76(4):437–40.

    Article  Google Scholar 

  12. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356.

    Article  CAS  Google Scholar 

  13. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655–9.

    Article  CAS  Google Scholar 

  14. Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004;171:1071–6.

    Article  Google Scholar 

  15. Ganeshappa A, Sundaram C, Lerner MA, et al. Role of the laparoscopic approach to cytoreductive nephrectomy in metastatic renal-cell carcinoma: does size matter? J Endourol. 2010;24:1289–92.

    Article  Google Scholar 

  16. Gershman B, Moreira DM, Boorjian SA, et al. Comprehensive characterization of the perioperative morbidity of cytoreductive nephrectomy. Eur Urol. 2016;69:84–91.

    Article  Google Scholar 

  17. Hanna N, Sun M, Meyer CP, et al. Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: a national cancer data base study. J Clin Oncol. 2016;34:3267–75.

    Article  Google Scholar 

  18. Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model: a population-based study. Lancet Oncol. 2013;14:141–8.

    Article  Google Scholar 

  19. Heng DY, Wells JC, Rini BI, et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. Eur Urol. 2014;66:704–10.

    Article  Google Scholar 

  20. Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009.

    Article  Google Scholar 

  21. Larcher A, Wallis C, Bex A, et al. Individualised indications for cytoreductive nephrectomy: which criteria define the optimal candidates? Eur Urol Oncol. 2019;4:365–78.

    Article  Google Scholar 

  22. Larcher A, Fallara G, Rosiello G, et al. Cytoreductive nephrectomy in metastatic patients with signs or symptoms: implications for Renal Cell Carcinoma Guidelines. Eur Urol. 2020;78(3):321–6.

    Article  Google Scholar 

  23. Ljungberg B, Albiges L, Bensalah K, et al. European association of urology guidelines on renal cell carcinoma: the 2020 update. Eur Urol. 2020.

    Google Scholar 

  24. Marchioni M, Kriegmair M, Heck M, et al. Development of a novel risk score to select the optimal candidate for cytoreductive nephrectomy among patients with metastatic renal cell carcinoma. Results from a Multi-institutional Registry (REMARCC). Eur Urol Oncol. 2020;S2588–9311(20)30218.

    Google Scholar 

  25. Matin SF, Madsen LT, Wood CG. Laparoscopic cytoreductive nephrectomy: the M.D. Anderson Cancer Center experience. Urology. 2006;68(3):528–32.

    Google Scholar 

  26. McIntosh AG, Umbreit EC, Holland LC, et al. Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy. Cancer. 2020;126(17):3950–60.

    Article  CAS  Google Scholar 

  27. Méjean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 2018;379(5):417–27.

    Article  Google Scholar 

  28. Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358:966–70.

    Article  CAS  Google Scholar 

  29. Mir MC, Matin SF, Bex A, et al. The role of surgery in the management of metastatic kidney cancer: an evidence-based collaborative review. Minerva Urol Nefrol. 2018;70:109–25.

    Google Scholar 

  30. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22:454–63.

    Article  Google Scholar 

  31. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277–90.

    Article  CAS  Google Scholar 

  32. Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1103–15.

    Article  CAS  Google Scholar 

  33. Nunez Bragayrac L, Hoffmeyer J, Abbotoy D, et al. Minimally invasive cytoreductive nephrectomy: a multi-institutional experience. World J Urol. 2016;34:1651–6.

    Article  Google Scholar 

  34. Ouzaid I, Capitanio U, Staehler M, et al. Surgical metastasectomy in renal cell carcinoma: a systematic review. Eur Urol Oncol. 2019;2(2):141–9.

    Article  Google Scholar 

  35. Pignot G, Thiery-Vuillemin A, Walz J, et al. Nephrectomy after complete response to immune checkpoint inhibitors for metastatic renal cell carcinoma: a new surgical challenge? Eur Urol. 2020;77(6):761–3.

    Article  Google Scholar 

  36. Rabets JC, Kaouk J, Fergany A, Finelli A, Gill IS, Novick AC. Laparoscopic versus open cytoreductive nephrectomy for metastatic renal cell carcinoma. Urology. 2004;64(5):930–4.

    Article  Google Scholar 

  37. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1116–27.

    Article  CAS  Google Scholar 

  38. Roussel E, Campi R, Larcher A, et al. Rates and predictors of perioperative complications in cytoreductive nephrectomy: analysis of the registry for metastatic renal cell carcinoma. Eur Urol Oncol. 2020;4:523–9.

    Article  Google Scholar 

  39. Singla N, Hutchinson RC, Ghandour RA, et al. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database. Urol Oncol. 2020;38:604.e9–e17.

    Google Scholar 

  40. Sorbellini M, Bratslavsky G. Renal cell carcinoma and prognostic factors predictive of survival. Urology. 2010;17:362–3.

    CAS  Google Scholar 

  41. Westerman ME, Shapiro DD, Tannir NM, et al. Survival following cytoreductive nephrectomy: a comparison of existing prognostic models. BJU Int. 2020;126(6):745–53.

    Article  Google Scholar 

  42. Zaid HB, Parker WP, Safdar NS, et al. Outcomes following complete surgical metastasectomy for patients with metastatic renal cell carcinoma: a systematic review and meta-analysis. J Urol. 2017;197(1):44–9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Hospital Clínico San Carlos, Complutense University of Madrid, Madrid, Spain

    Roser Vives Dilme, Juan Gómez Rivas & Jesús Moreno Sierra

  2. Unit of Urological Robotic Surgery and Renal Transplantation, Careggi Hospital, University of Florence, Florence, Italy

    Riccardo Campi

  3. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

    Riccardo Campi

  4. European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group, Arnhem, The Netherlands

    Riccardo Campi

  5. Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain

    Javier Puente

Authors
  1. Roser Vives Dilme
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Juan Gómez Rivas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Riccardo Campi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Javier Puente
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jesús Moreno Sierra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roser Vives Dilme .

Editor information

Editors and Affiliations

  1. Princess Alexandra Hospital, Harlow, UK

    Sanchia S. Goonewardene

  2. North Bristol NHS Trust, Bristol, UK

    Raj Persad

  3. Syracuse, NY, USA

    David Albala

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Vives Dilme, R., Gómez Rivas, J., Campi, R., Puente, J., Moreno Sierra, J. (2022). Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma. In: Goonewardene, S.S., Persad, R., Albala, D. (eds) Robotic Surgery for Renal Cancer. Management of Urology. Springer, Cham. https://doi.org/10.1007/978-3-031-11000-9_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-11000-9_24

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-10999-7

  • Online ISBN: 978-3-031-11000-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation